Ocuphire Pharma Inc. Common Stock
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
OCUP Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$4.0800 |
Previous Close Volume |
81550 |
Latest News
- Ocuphire Pharma Announces Acquisition of Opus Genetics 22 Oct 2024 16:31:28
- Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology 30 Sep 2024 08:01:17
- Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia 05 Sep 2024 08:03:32
- Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update 13 Aug 2024 08:01:52
- Ocuphire Pharma to Present at Two Investor Conferences in August 08 Aug 2024 08:01:38
- Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July 10 Jul 2024 08:01:50
- Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June 06 Jun 2024 08:01:46
- Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update 10 May 2024 08:16:46
- Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting 06 May 2024 08:16:46
- Ocuphire Pharma to Present at the Aegis Virtual Conference 03 May 2024 08:16:48
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery 11 Apr 2024 10:17:05
- Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris 01 Apr 2024 07:17:31
- Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update 08 Mar 2024 08:17:19
- Ocuphire Pharma to Present in the BIO CEO & Investor Conference 23 Feb 2024 08:02:13
- Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15 Feb 2024 16:32:13
- Ocuphire Pharma Strengthens Leadership Team with Key Appointments 14 Feb 2024 08:02:05
- Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference 05 Feb 2024 08:02:29
- Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 24 Jan 2024 16:32:39